SHARESIFT
Healthcare · data ~15-min delayed
256.03 USD -1.02%
| Price | 256.03 USD |
| Day change | -1.02% |
| Market cap | 617.01B |
| 52-week range | 182.94 – 281.07 |
| P/E (trailing) | 29.7 |
| Dividend yield | 2.09% |
| Payout ratio | 60.79% |
| Return on equity | 25.74% |
| Debt / equity | 58% |
| Beta | 0.23 |
| Sector | Healthcare |
| Value score | 35 / 100 |
How the value score is calculated: 13 published tests, weighted to 100.
Johnson & Johnson (JNJ) scores 35/100 on this site's value model, in the lower band: most of the valuation measures it checks sit on the richer side. It trades at 29.7 times trailing earnings and is classified in Healthcare. The dividend yield is 2.09%, paid from 61% of earnings. Return on equity is 26%, with debt at 58% of equity. On its filings it passes 4 of the nine Piotroski checks, a mixed picture. Its Altman Z-Score places it in the safe zone. These are automated readings of reported figures, not a recommendation.
Piotroski F-Score 4 / 9 — nine pass/fail checks on profitability, leverage and efficiency, comparing the latest financial year with the one before.
Altman Z-Score 5.41 — Safe zone.
Updated · prices ~15-min delayed, fundamentals as last reported
Open full interactive analysis →See how it ranks: US stocks by value score
Value scoring · Piotroski F-Score · Altman Z · technicals · dividends — free, no sign-up.